<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.infectagentscancer.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Infectious Agents and Cancer - Latest Articles</title>
        <link>http://www.infectagentscancer.com</link>
        <description>The latest research articles published by Infectious Agents and Cancer</description>
        <dc:date>2012-04-19T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/7/1/10" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/7/1/9" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/7/1/8" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/7/1/7" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/7/1/6" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/7/1/5" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/7/1/4" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/7/1/3" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/7/1/2" />
                                <rdf:li rdf:resource="http://www.infectagentscancer.com/content/7/1/1" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.infectagentscancer.com/content/7/1/10">
        <title>Detection of helicobacter pylori in benign laryngeal lesions by polymerase chain reaction: a cross sectional study</title>
        <description>Background:
Although Helicobacter Pylori (HP) was detected in some cases of chronic laryngitis, the results were not confirmed by polymerase chain reaction (PCR). By this time, it has not been found in laryngeal lesions by in house PCR, the most sensitive method for detecting the genome tracks. Regarding the previous results and also few numbers of studies about the presence of HP in benign laryngeal lesions, specifically by PCR, we aimed to investigate the presence of HP in benign laryngeal lesions by in-house PCR.
Methods:
The samples were taken from 55 patients with benign laryngeal lesions and frozen in 20degreesC. One milliliter (ml) of lysis buffer was added to 100 mg (mg) of each sample and the tube was placed in 56degreesC overnight. Then DNA extraction was carried out.
Results:
To find HP DNA, in-house PCR was performed that revealed 5 positive results among 55 patients with benign laryngeal lesions. Of them, 3 were polyp, 1 was nodule and 1 was papilloma.
Conclusion:
Although the number of positive results was not a lot in this study, it was in contrast with previous studies which could not find any HP tracks in benign laryngeal lesions by other methods. More studies about the prevalence of HP in benign laryngeal lesions improve judging about the effect of this infection on benign laryngeal lesions.</description>
        <link>http://www.infectagentscancer.com/content/7/1/10</link>
                <dc:creator>Farzad Izadi</dc:creator>
                <dc:creator>Aslan Ahmadi</dc:creator>
                <dc:creator>Shadi Ghourchian</dc:creator>
                <dc:creator>Ahmad Daneshi</dc:creator>
                <dc:creator>Faramarz Memari</dc:creator>
                <dc:creator>Ehsan Khadivi</dc:creator>
                <dc:creator>Shabahang Mohammadi</dc:creator>
                <dc:source>Infectious Agents and Cancer 2012, null:10</dc:source>
        <dc:date>2012-04-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-7-10</dc:identifier>
                                <prism:require>/content/figures/1750-9378-7-10-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2012-04-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/7/1/9">
        <title>Activating KIR/HLA complexes in classic Kaposi&apos;s Sarcoma</title>
        <description>Background:
Classic Kaposi&apos;s Sarcoma (cKS) is a rare vascular tumor associated with Human Herpesvirus 8 (KSHV) infection, nevertheless not all KSHV-infected individuals have cKS.ObjectiveWe investigated whether particular KIR/HLA receptor/ligand genotypes would be preferentially present in KSHV-infected and uninfected individuals who have or have not developed cKS.
Methods:
KIR/HLA genotypes were analyzed by molecular genotyping in 50 KSHV-infected individuals who did or did not have cKS and in 33 age-and sex-matched KSHV seronegative individuals.
Results:
There was no association of individual KIR, HLA or receptor ligand combinations with KSHV infection. However, activating KIR and KIR/HLA genotypes were significantly more frequent in cKS cases, specifically KIR3DS1, KIR2DS1, and KIR2DS1 with its HLA-C2 ligand.
Conclusion:
A nonspecific inflammatory response triggered by activation of NK cells upon KIR-HLA interaction could be associated with the pathogenesis of KS.</description>
        <link>http://www.infectagentscancer.com/content/7/1/9</link>
                <dc:creator>Franca Guerini</dc:creator>
                <dc:creator>Roberta Mancuso</dc:creator>
                <dc:creator>Simone Agostini</dc:creator>
                <dc:creator>Cristina Aglairdi</dc:creator>
                <dc:creator>Milena Zanzottera</dc:creator>
                <dc:creator>Ambra Hernis</dc:creator>
                <dc:creator>Athanasia Tourlaki</dc:creator>
                <dc:creator>Maria Calvo</dc:creator>
                <dc:creator>Monica Bellinvia</dc:creator>
                <dc:creator>Lucia Brambilla</dc:creator>
                <dc:creator>Mario Clerici</dc:creator>
                <dc:source>Infectious Agents and Cancer 2012, null:9</dc:source>
        <dc:date>2012-04-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-7-9</dc:identifier>
                                <prism:require>/content/figures/1750-9378-7-9-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2012-04-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/7/1/8">
        <title>Chlamydia psittaci in Ocular Adnexa MALT Lymphoma: a possible role in lymphomagenesis and a different geographical distribution</title>
        <description>Ocular adnexa MALT-lymphomas represent approximatively 5-15% of all extranodal lymphomas. Almost 75% of OAMLs are localized in orbital fat, while 25% of cases involves conjunctive. MALT-lymphomas often recognize specific environmental factors responsible of lymphoma development and progression. In particular as Helicobacter pylori in gastric MALT lymphomas, other bacterial infections have been recognized related to MALT lymphomas in specific site. Recently Chlamydia psittaci has been identified in Ocular Adnexa MALT lymphomas, with variable frequence dependently from geographic areas. Thus bacterial infection is responsible of clonal selection on induced MALT with subsequent lymphoma development. Moreover Chlamydia psittaci could promote chromosomal aberration either through genetic instability as a consequence of induced proliferation and probably through DNA oxidative damage. The most common translocation described in MALT lymphomas affects NF-kB pathway with a substantial antiapoptotic effect. Several therapeutic approaches are now available, but the use of antibiotic-therapy in specific cases, although with conflicting results, could improve the treatment of ocular adnexa MALT lymphomas. In this review we analyse the most relevant features of Ocular adnexa MALT lymphomas, underlining specific biological characteristics mainly related to the potential role of Chlamydia psittaci in lymphomagenesis.</description>
        <link>http://www.infectagentscancer.com/content/7/1/8</link>
                <dc:creator>Francesca Collina</dc:creator>
                <dc:creator>Anna De Chiara</dc:creator>
                <dc:creator>Amalia De Renzo</dc:creator>
                <dc:creator>Gaetano De Rosa</dc:creator>
                <dc:creator>Gerardo Botti</dc:creator>
                <dc:creator>Renato Franco</dc:creator>
                <dc:source>Infectious Agents and Cancer 2012, null:8</dc:source>
        <dc:date>2012-04-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-7-8</dc:identifier>
                                <prism:require>/content/figures/1750-9378-7-8-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2012-04-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/7/1/7">
        <title>Innate immunity and hepatitis C virus infection: a microarray&apos;s view</title>
        <description>Hepatitis C virus (HCV) induces a chronic infection in more than two-thirds of HCV infected subjects. The inefficient innate and adaptive immune responses have been shown to play a major pathogenetic role in the development and persistence of HCV chronic infection.Several aspects of the interactions between the virus and the host immune system have been clarified and, in particular, mechanisms have been identified which underlie the ability of HCV to seize and subvert innate as well as adaptive immune responses.The present review summarizes recent findings on the interaction between HCV infection and innate immune response whose final effect is the downstream inefficient development of antigen-specific adaptive immunity, thereby contributing to virus persistence.</description>
        <link>http://www.infectagentscancer.com/content/7/1/7</link>
                <dc:creator>Luigi Buonaguro</dc:creator>
                <dc:creator>Annacarmen Petrizzo</dc:creator>
                <dc:creator>Maria Lina Tornesello</dc:creator>
                <dc:creator>Franco Buonaguro</dc:creator>
                <dc:source>Infectious Agents and Cancer 2012, null:7</dc:source>
        <dc:date>2012-03-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-7-7</dc:identifier>
                                <prism:require>/content/figures/1750-9378-7-7-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2012-03-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/7/1/6">
        <title>HIV Co-receptor Usage in HIV-related Non-Hodgkin&apos;s Lymphoma</title>
        <description>In this study 15 banked samples of HIV-related Non-Hodgkin&apos;s Lymphoma (NHL) cases were tested for HIV co-receptor usage and SDF1 3&apos;A polymorphism. Reportable tropism from 9 plasma samples had 1 (11.1%) HIV case with CXCR4 and 8 (88.9%) with CCR5 usage, even though most of the cases occurred at a late stage of HIV (2/3 had CD4 counts below 200), where expected CXCR4 usage would be 60%. Based on the expected proportion of less than 50% CCR5 in chronically infected individuals, this would suggest that in NHL may be associated with CCR5 usage (P = 0.04).</description>
        <link>http://www.infectagentscancer.com/content/7/1/6</link>
                <dc:creator>Erin Reid</dc:creator>
                <dc:creator>Sheldon Morris</dc:creator>
                <dc:source>Infectious Agents and Cancer 2012, null:6</dc:source>
        <dc:date>2012-03-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-7-6</dc:identifier>
                                <prism:require>/content/figures/1750-9378-7-6-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2012-03-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/7/1/5">
        <title>A case-control study of Burkitt lymphoma in East Africa: are local health facilities an appropriate source of representative controls?</title>
        <description>Background:
We investigated the feasibility and appropriateness of enrolling controls for Burkitt lymphoma (BL) from local health facilities in two regions in Uganda.
Methods:
BL case data were compiled from two local hospitals with capacity to diagnose and treat BL in North-west and North-central regions of Uganda during 1997 to 2009. Local health facility data were compiled from children attending four representative local health facilities in the two regions over a two week period in May/June 2010. Age and sex patterns of BL cases and children at local facilities were compared and contrasted using frequency tables.
Results:
There were 999 BL cases diagnosed in the study area (92% of all BL cases treated at the hospitals): 64% were from North-central and 36% from North-west region. The mean age of BL cases was 7.0 years (standard deviation [SD] 3.0). Boys were younger than girls (6.6 years versus 7.2 years, P = 0.004) and cases from North-central region were younger than cases from North-west region (6.8 years versus 7.3 years, P = 0.014). There were 1012 children recorded at the four local health facilities: 91% at facilities in North-central region and 9% from facilities in North-west region. Daily attendance varied between 1 to 75 children per day. The mean age of children at health facilities was 2.2 years (SD 2.8); it did not differ by sex. Children at North-central region facilities were younger than children at North-west region facilities (1.8 years versus 6.6 years, P &lt; 0.001).
Conclusions:
While many children attend local health facilities, confirming feasibility of obtaining controls, their mean age is much lower than BL cases. Health facilities may be suitable for obtaining young, but not older, controls.</description>
        <link>http://www.infectagentscancer.com/content/7/1/5</link>
                <dc:creator>Sonya Baik</dc:creator>
                <dc:creator>Mike Mbaziira</dc:creator>
                <dc:creator>Makeda Williams</dc:creator>
                <dc:creator>Martin Ogwang</dc:creator>
                <dc:creator>Tobias Kinyera</dc:creator>
                <dc:creator>Benjamin Emmanuel</dc:creator>
                <dc:creator>John Ziegler</dc:creator>
                <dc:creator>Steven Reynolds</dc:creator>
                <dc:creator>Sam Mbulaiteye</dc:creator>
                <dc:source>Infectious Agents and Cancer 2012, null:5</dc:source>
        <dc:date>2012-03-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-7-5</dc:identifier>
                                <prism:require>/content/figures/1750-9378-7-5-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2012-03-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/7/1/4">
        <title>Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization</title>
        <description>Background:
Recent emerging evidences identify Human Papillomavirus (HPV) related Head and Neck squamous cell carcinomas (HN-SCCs) as a separate subgroup among Head and Neck Cancers with different epidemiology, histopathological characteristics, therapeutic response to chemo-radiation treatment and clinical outcome. However, there is not a worldwide consensus on the methods to be used in clinical practice. The endpoint of this study was to demonstrate the reliability of a triple method which combines evaluation of: 1. p16 protein expression by immunohistochemistry (p16-IHC); 2. HPV-DNA genotyping by consensus HPV-DNA PCR methods (Consensus PCR); and 3 viral integration into the host by in situ hybridization method (ISH). This triple method has been applied to HN-SCC originated from oral cavity (OSCC) and oropharynx (OPSCC), the two anatomical sites in which high risk (HR) HPVs have been clearly implicated as etiologic factors. Methylation-Specific PCR (MSP) was performed to study inactivation of p16-CDKN2a locus by epigenetic events. Reliability of multiple methods was measured by Kappa statistics.
Results:
All the HN-SCCs confirmed HPV positive by PCR and/or ISH were also p16 positive by IHC, with the latter showing a very high level of sensitivity as single test (100% in both OSCC and OPSCC) but lower specificity level (74% in OSCC and 93% in OPSCC).Concordance analysis between ISH and Consensus PCR showed a faint agreement in OPSCC (&#954; = 0.38) and a moderate agreement in OSCC (&#954; = 0.44). Furthermore, the addition of double positive score (ISHpositive and Consensus PCR positive) increased significantly the specificity of HR-HPV detection on formalin-fixed paraffin embedded (FFPE) samples (100% in OSCC and 78.5% in OPSCC), but reduced the sensitivity (33% in OSCC and 60% in OPSCC). The significant reduction of sensitivity by the double method was compensated by a very high sensitivity of p16-IHC detection in the triple approach.
Conclusions:
Although HR-HPVs detection is of utmost importance in clinical settings for the Head and Neck Cancer patients, there is no consensus on which to consider the &apos;golden standard&apos; among the numerous detection methods available either as single test or combinations. Until recently, quantitative E6 RNA PCR has been considered the &apos;golden standard&apos; since it was demonstrated to have very high accuracy level and very high statistical significance associated with prognostic parameters. In contrast, quantitative E6 DNA PCR has proven to have very high level of accuracy but lesser prognostic association with clinical outcome than the HPV E6 oncoprotein RNA PCR. However, although it is theoretically possible to perform quantitative PCR detection methods also on FFPE samples, they reach the maximum of accuracy on fresh frozen tissue. Furthermore, worldwide diagnostic laboratories have not all the same ability to analyze simultaneously both FFPE and fresh tissues with these quantitative molecular detection methods. Therefore, in the current clinical practice a p16-IHC test is considered as sufficient for HPV diagnostic in accordance with the recently published Head and Neck Cancer international guidelines. Although p16-IHC may serve as a good prognostic indicator, our study clearly demonstrated that it is not satisfactory when used exclusively as the only HPV detecting method. Adding ISH, although known as less sensitive than PCR-based detection methods, has the advantage to preserve the morphological context of HPV-DNA signals in FFPE samples and, thus increase the overall specificity of p16/Consensus PCR combination tests.</description>
        <link>http://www.infectagentscancer.com/content/7/1/4</link>
                <dc:creator>Giuseppe Pannone</dc:creator>
                <dc:creator>Vito Rodolico</dc:creator>
                <dc:creator>Angela Santoro</dc:creator>
                <dc:creator>Lorenzo Lo Muzio</dc:creator>
                <dc:creator>Renato Franco</dc:creator>
                <dc:creator>Gerardo Botti</dc:creator>
                <dc:creator>Gabriella Aquino</dc:creator>
                <dc:creator>Maria Carmela Pedicillo</dc:creator>
                <dc:creator>Simona Cagiano</dc:creator>
                <dc:creator>Giuseppina Campisi</dc:creator>
                <dc:creator>Corrado Rubini</dc:creator>
                <dc:creator>Silvana Papagerakis</dc:creator>
                <dc:creator>Gaetano De Rosa</dc:creator>
                <dc:creator>Maria Lina Tornesello</dc:creator>
                <dc:creator>Franco Buonaguro</dc:creator>
                <dc:creator>Stefania Staibano</dc:creator>
                <dc:creator>Pantaleo Bufo</dc:creator>
                <dc:source>Infectious Agents and Cancer 2012, null:4</dc:source>
        <dc:date>2012-02-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-7-4</dc:identifier>
                                <prism:require>/content/figures/1750-9378-7-4-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2012-02-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/7/1/3">
        <title>Cervical cytological changes in HIV-infected patients attending care and treatment clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania</title>
        <description>Background:
Tanzania is among Sub-Saharan countries mostly affected by the HIV and AIDS pandemic, females being more vulnerable than males. HIV infected women appear to have a higher rate of persistent infection by high risk types of human papillomavirus (HPV) strongly associated with high-grade squamous intraepithelial lesions (HSIL) and invasive cervical carcinoma. Furthermore, although HIV infection and cervical cancer are major public health problems, the frequency and HIV/HPV association of cervical cancer and HSIL is not well documented in Tanzania, thus limiting the development of preventive and therapeutic strategies.
Methods:
A prospective unmatched, case-control study of HIV-seropositive, &#8805; 18 years of age and consenting non-pregnant patients attending the care and treatment center (CTC) at Muhimbili National Hoospital (MNH) as cases was done between 2005 and 2006. HIV seronegative, non-pregnant and consenting women recruited from the Cervical Cancer Screening unit (CCSU) at ORCI were used as controls while those who did not consent to study participation and/or individuals under &lt; 18 years were excluded. Pap smears were collected for routine cytodiagnosis and P53 immunohistochemistry (IHC). Cervical lesions were classified according to the Modified Bethesda System.
Results:
A total of 170 participants from the two centers were recruited including 50 HIV-seronegative controls were from the CCSU. Ages ranged from 20-66 years (mean 40.5 years) for cases and 20-69 years (mean 41.6 years) for controls. The age group 36-45 years was the most affected by HIV (39.2%, n = 47). Cervicitis, squamous intraepithelial lesions (SIL) and carcinoma constituted 28.3% (n = 34), 38.3% (n = 46) and 5.8% (n = 7) respectively among cases, and 28% (n = 14), 34% (n = 17) and 2% (n = 1) for controls, although this was not statistically significant (P-value = 0.61). IHC showed that p53 was not detectable in HPV + Pap smears and cell blocks indicating possible degradation.
Conclusions:
The frequency of SIL and carcinoma appeared to be higher among HIV-infected women on HAART compared to seronegative controls and as expected increased with age. HIV seropositive patients appeared to present earlier with SIL compared to those HIV seronegative suggesting a role of HIV in altering the natural history of HPV infection and cervical lesions. The absence of p53 immunoreactivity in HPV + lesions is indicative of the ability of HPV E6 proteins to interact with the tumor suppressor gene and pave way for viral-induced oncogenesis in the studied Tanzanian women.</description>
        <link>http://www.infectagentscancer.com/content/7/1/3</link>
                <dc:creator>Amos Mwakigonja</dc:creator>
                <dc:creator>Liset Maria Torres</dc:creator>
                <dc:creator>Henry Mwakyoma</dc:creator>
                <dc:creator>Ephata Kaaya</dc:creator>
                <dc:source>Infectious Agents and Cancer 2012, null:3</dc:source>
        <dc:date>2012-02-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-7-3</dc:identifier>
                                <prism:require>/content/figures/1750-9378-7-3-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2012-02-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/7/1/2">
        <title>Hepatitis C virus to hepatocellular carcinoma</title>
        <description>Hepatitis C virus causes acute and chronic hepatitis and can lead to permanent liver damage and hepatocellular carcinoma (HCC) in a significant number of patients via oxidative stress, insulin resistance (IR), fibrosis, liver cirrhosis and HCV induced steatosis. HCV induced steatosis and oxidative stress causes steato-hepatitis and these pathways lead to liver injury or HCC in chronic HCV infection. Steatosis and oxidative stress crosstalk play an important role in liver damage in HCV infection. This Review illustrates viral and host factors which induce Oxidative stress, steatosis and leads toward HCC. It also expresses Molecular cascade which leads oxidative stress and steatosis to HCC.</description>
        <link>http://www.infectagentscancer.com/content/7/1/2</link>
                <dc:creator>Shah Jahan</dc:creator>
                <dc:creator>Usman Ashfaq</dc:creator>
                <dc:creator>Muhammad Qasim</dc:creator>
                <dc:creator>Saba Khaliq</dc:creator>
                <dc:creator>Muhammad Javed Saleem</dc:creator>
                <dc:creator>Nadeem Afzal</dc:creator>
                <dc:source>Infectious Agents and Cancer 2012, null:2</dc:source>
        <dc:date>2012-01-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-7-2</dc:identifier>
                                <prism:require>/content/figures/1750-9378-7-2-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2012-01-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.infectagentscancer.com/content/7/1/1">
        <title>mTOR Inhibitors: A Novel Class of Anti Cancer Agents</title>
        <description>N/A</description>
        <link>http://www.infectagentscancer.com/content/7/1/1</link>
                <dc:creator>Haris Riaz</dc:creator>
                <dc:creator>Talha Riaz</dc:creator>
                <dc:creator>Syed Hussain</dc:creator>
                <dc:source>Infectious Agents and Cancer 2012, null:1</dc:source>
        <dc:date>2012-01-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1750-9378-7-1</dc:identifier>
                                <prism:require>/content/figures/1750-9378-7-1-toc.gif</prism:require>
                <prism:publicationName>Infectious Agents and Cancer</prism:publicationName>
        <prism:issn>1750-9378</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2012-01-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

